†Staging of melanoma according to the AJCC eighth edition. Treatment response evaluation at t₁ and t₂ were each related to the baseline scan t₀. Overall response by taking imaging and clinical decisions into account, categorized as (Non-)Responders, (N)R. Patients with a metastatic involvement of the bone are marked with (*), of the spleen with (†). In those patients, the bone or the spleen, respectively, was excluded from further evaluation. In patient no. 7, the attenuation map at t₁ was erroneous in the upper abdomen, so no reliable SULmean of the spleen could be measured. Spleen SUV t₁-t₀ (%): the relative change of ¹⁸F-FDG-uptake of the spleen between t₁ and t₀.

*Patients with a metastatic involvement of the bone.

†Patients with a metastatic involvement of the spleen.

AJCC, American Joint Committee on Cancer; CMR, complete metabolic response; CTLA-4, cytotoxic T-lymphocyte-associated protein-4; ¹⁸F-FDG, [¹⁸F]-labeled fluorodeoxyglucose; iCR, immune complete response; iPD, immune progressive disease; iPR, immune partial response; iSD, immune stable disease; N/A, not available; NR, non-responders; PD1, programmed-death-1; PERCIST, PET response criteria in solid tumors; PMD, progressive metabolic disease; PMR, partial metabolic response; SMD, stable metabolic disease; SULmean, standardized uptake value lean body mass; SUV, standardized uptake value.